GLP-1 Weight Drugs May Weigh on Fat Use, Not Just Appetite
TL;DR Summary
A new mouse study suggests long-term weight loss from GLP-1 drugs like Ozempic and Wegovy may rely not only on suppressing appetite but also on energy mobilization governed by AgRP hunger neurons. When these neurons were disrupted in female mice, semaglutide still reduced eating, but fat mobilization and the overall weight-loss effect weakened, leading to weight regain within about two weeks. Normal-functioning neurons maintained weight loss, and disruptions involving Sirt1 signaling partially reversed the effect. Results are preclinical and observed mainly in female mice, so more research is needed to understand implications for humans.
- GLP-1s May Be Working in an Entirely Different Way Than We Thought ScienceAlert
- New study may change how we think about GLP-1s YaleNews
- New Weight Loss Pills Barely Worked in Mice Until Scientists Uncovered a Brain Circuit Controlling Cravings Medical Daily
- GLP-1 obesity drugs activate hunger neurons to drive fat loss 동아사이언스
- The hunger switch Ozempic doesn’t actually turn off BakeryAndSnacks.com
Reading Insights
Total Reads
0
Unique Readers
11
Time Saved
5 min
vs 6 min read
Condensed
92%
1,155 → 94 words
Want the full story? Read the original article
Read on ScienceAlert